Amunix, Inc. Company Profile | Company Information

Amunix creates protein pharmaceuticalswith new, valuable features and for applicationz with unmet needs. Our strength is in protei design and the discovergyresearch process. Clinical development is performed in collaboratiojwith partners, typically large pharmaceuticap companies. Amunix stands for ‘non-immunogenic (protein) therapeutics’. One way to make a protein non-immunogenic is to maximize it’s flexibility, by maximizinbg glycine content andminimizinb structure.
This approach has led to our ‘recombinant PEGylation” technology (rPEG) for serum halflife This involves genetically fusinga 300-600 amino acid unstructured proteihn tail to an existing pharmaceutical protein, such as IFN or hGH. Because the apparent moleculadr weight of such an unstructuredx protein chain isabout 15-folsd larger than its actual molecular weight, the serumj halflife of the protein is greatl increased. In contrast to traditional PEGylation, which requires chemical conjugationand repurification, the manufacturinf process is greatly simplifiec and the product is homogeneous.
Anothef way to make proteins non-immunogenic involves takingv theopposite approach, creating a foldee domain with an exceptionally rigid structure. This approacb is naturally foundin microproteins, which are small protein domains of 15-60AAz with a high disulfide content that makes them extremely stable. …
livejournal.com